Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Affimed NV AFMD

Healthcare Biotechnology
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1... see more

Recent & Breaking News (NDAQ:AFMD)

Affimed to Present at the H.C. Wainwright Annual Global Investment Conference

GlobeNewswire September 7, 2023

Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability

GlobeNewswire August 22, 2023

Affimed Reports Second Quarter 2023 Financial Results and Highlights Operational Progress

GlobeNewswire August 10, 2023

Affimed to Report Second Quarter 2023 Financial Results & Corporate Update on August 10, 2023

GlobeNewswire August 3, 2023

Affimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotech's SNK01 NK Cells

GlobeNewswire July 31, 2023

Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board

GlobeNewswire June 22, 2023

Affimed Announces Acceptance of Abstracts at the 17th International Conference on Malignant Lymphoma (17-ICML)

GlobeNewswire June 9, 2023

Affimed Presents AFM24 Monotherapy Data in Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology and Provides Strategic Update on AFM24 Development Plan

GlobeNewswire June 3, 2023

Affimed to Present at the 2023 Jefferies Healthcare Conference

GlobeNewswire May 30, 2023

Affimed Announces Publication of AFM24 Clinical Abstracts for the Annual Meeting of the American Society of Clinical Oncology

GlobeNewswire May 25, 2023

Affimed Reports First Quarter 2023 Financial Results and Highlights Operational Progress

GlobeNewswire May 23, 2023

Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy

GlobeNewswire May 23, 2023

Affimed Announces Annual General Meeting of Shareholders

GlobeNewswire May 22, 2023

Affimed to Report First Quarter 2023 Financial Results & Corporate Update on May 23, 2023

GlobeNewswire May 16, 2023

Affimed Announces Abstracts at the Annual Meeting of the European Hematology Association

GlobeNewswire May 11, 2023

Affimed Announces AFM24 Clinical Abstracts Accepted for the Annual Meeting of the American Society of Clinical Oncology (ASCO)

GlobeNewswire April 26, 2023

Affimed Shares Preclinical Data on AFM13's Mechanism of Action Demonstrating Its Potential to Induce Serial Killing at the American Association for Cancer Research Annual Meeting

GlobeNewswire April 17, 2023

Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meeting 2023

GlobeNewswire April 16, 2023

Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

GlobeNewswire April 6, 2023

Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia

GlobeNewswire March 29, 2023